Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
Charles Schwab Investment Management Inc. increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback